Eris Lifesciences Limited — Results, 04-02-2025: Integrated Filing- Financial

Eris Lifesciences Limited reported its financial results for the quarter and nine months ended December 31, 2024. Revenue from operations reached ₹727.45 crore, while the net profit for the period was ₹86.93 crore. The company has been impacted by recent acquisitions in the nephrology, dermatology, and Indian branded formulations sectors, making year-on-year comparisons challenging. The ongoing acquisitions, including a significant stake in Levim Lifetech, may present both strategies for growth and potential integration risks. Overall, this update suggests flexibility in growth avenues, fostering a positive outlook among investors.